Previous 10 | Next 10 |
Eiger BioPharmaceuticals ( EIGR ) is developing lonafarnib, an oral prenylation inhibitor, to treat Hepatitis D and Progeria. Hepatitis D is typically a superinfection on top of Hepatitis B, leading to a more severe form of the disease. It affects 15-20 million people worldwide, and there is n...
Eiger BioPharmaceuticals (NASDAQ: EIGR ): Q1 GAAP EPS of -$0.62 beats by $0.19 . More news on: Eiger BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , May 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a busin...
The first participants have been dosed in a 120-subject Phase 2 clinical trial at Stanford University School of Medicine evaluating Eiger BioPharmaceuticals' ( EIGR -0.6% ) peginterferon lambda (lambda) in patients with mild COVID-19 infection. More news on: Eiger BioPharmaceuticals, I...
PALO ALTO, Calif. , April 30, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in a Phase 2 study of p...
PALO ALTO, Calif. , April 27, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the European Medicines Agency (EMA) has completed i...
Citing COVID-19 disruptions, Eiger BioPharmaceuticals (NASDAQ: EIGR ) announces that enrollment in its Phase 3 D-LIVR study evaluating the combination of lonafarnib and ritonavir with or without PEGylated interferon-alfa-2a in patients with chronic hepatitis D virus (HDV) infection will ...
PALO ALTO, Calif. , April 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today provided an update on the impact of the rapidly progressing glob...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) has completed NDA submission for lonafarnib for the treatment of Progeria and Progeroid Laminopathies. More news on: Eiger BioPharmaceuticals, Inc., Healthcare stocks news, Read more ...
PALO ALTO, Calif., March 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed submission to the U.S. F...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...